Repeated hallucinations matter because they are predictable. If the same invented package appears across prompts or agents, an attacker can register it once and wait for multiple victims. That makes slopsquatting scalable, not random. Security teams should monitor for recurring hallucinated names and block them centrally across repositories and build pipelines.
Why This Matters for Security Teams
Repeated package hallucinations turn a one-off AI mistake into a reusable supply chain risk. When the same invented dependency appears across chats, code assistants, or autonomous agents, it creates a stable target that can be registered, poisoned, or parked by an attacker. That is why AppSec teams should treat recurring hallucinated names as an indicator of systemic exposure, not as isolated user error. NIST’s NIST SP 800-53 Rev 5 Security and Privacy Controls is useful here because it frames software supply chain governance, integrity, and monitoring as operational controls rather than ad hoc hygiene.
The practical risk is amplified in environments where developers copy AI-generated dependency suggestions directly into manifests, lockfiles, or build scripts. Once a hallucinated package name becomes familiar, it can propagate through pull requests, internal templates, and agent workflows faster than human reviewers can validate it. Security teams often focus on whether an AI answer is correct in the moment, but the real issue is whether the false package name can be repeated, searched, and exploited at scale. In practice, many security teams encounter this only after a malicious package has already been published under the hallucinated name, rather than through intentional dependency governance.
How It Works in Practice
Repeated hallucinations matter because they create a predictable “collision surface” between AI output and public package ecosystems. A package name that appears once may be noise; a package name that appears repeatedly across prompts, models, or agents becomes a candidate for centralized blocking, alerting, and policy enforcement. AppSec teams should treat that repetition as enrichment data for dependency risk management, not as a curiosity.
Operationally, the right response is to connect AI usage telemetry with software composition analysis, dependency allowlisting, and build-time verification. Teams should look for recurring invented names in code assistant logs, issue trackers, chat transcripts, and CI/CD artifacts, then cross-check those names against package registries before any install or import step. This is consistent with the broader direction of supply chain guidance in the CISA SBOM practical guide and with secure software governance practices in SLSA.
- Block known hallucinated names at the registry, proxy, or package manager policy layer.
- Scan prompts, agent outputs, and build logs for recurring invented dependency strings.
- Require human review before introducing any package that was first seen in an AI suggestion.
- Correlate repeated hallucinations with developer tools, repositories, and agent identities to find the exposure path.
This also matters for agentic AI because an autonomous agent can repeat the same hallucinated dependency across multiple tasks, turning one bad suggestion into a broad operational pattern. Where organisations use managed build agents or software bots, the repeatable nature of the error can make the hallucination look “validated” simply because it is consistent. These controls tend to break down when AI-generated dependencies are allowed to flow straight into ephemeral CI jobs, because there is no durable review point before the package resolution step.
Common Variations and Edge Cases
Tighter dependency controls often increase workflow friction, requiring organisations to balance developer speed against supply chain assurance. That tradeoff is especially visible when teams use multiple models, multiple package ecosystems, or private registries with inconsistent naming rules. There is no universal standard for this yet, so current guidance suggests focusing on repeatability, provenance, and enforceable policy rather than trying to score every hallucination equally.
Edge cases emerge when the hallucinated name is close to a legitimate package, when internal mirrors obscure public registry lookups, or when an agent generates a package that does not exist yet but is still technically valid to reserve. In those situations, the security question is not only whether the package exists, but whether the naming pattern is recurring enough to justify preemptive blocking. This is where AppSec and platform engineering need a shared taxonomy for false dependencies and a clear exception process.
For organisations with stronger governance maturity, recurring hallucinations can also inform OWASP guidance for LLM application risks, especially where prompt injection, tool misuse, and unsafe output handling intersect with build automation. The key is to treat repeated hallucination as an early warning signal for software supply chain abuse, not merely a model quality issue.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
OWASP Agentic AI Top 10 and MITRE ATLAS address the attack and risk surface, while NIST CSF 2.0, NIST AI RMF and NIST AI 600-1 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST CSF 2.0 | ID.RA-1 | Recurring hallucinations are a supply chain risk that should be identified and tracked. |
| NIST AI RMF | AI RMF addresses trustworthy AI governance and output reliability issues here. | |
| OWASP Agentic AI Top 10 | Agentic systems can repeatedly propagate the same hallucinated package names. | |
| MITRE ATLAS | AML.TA0002 | Adversaries can exploit predictable AI behaviour to seed malicious package names. |
| NIST AI 600-1 | GenAI profile guidance is relevant to validating and monitoring model-generated content. |
Catalog repeated hallucinated dependencies as an identified risk and feed them into ongoing risk treatment.
